Jump to content
Main menu
Navigation
●Main page
●Contents
●Current events
●Random article
●About Wikipedia
●Contact us
●Donate
Contribute
●Help
●Learn to edit
●Community portal
●Recent changes
●Upload file
Search
●Create account
●Log in
●Create account
● Log in
Pages for logged out editors learn more
●Contributions
●Talk
(Top)
1
References
2
External links
Belatacept
●فارسی
●Français
●Italiano
●ଓଡ଼ିଆ
●Polski
●Português
●Српски / srpski
●Srpskohrvatski / српскохрватски
●Tiếng Việt
Edit links
●Article
●Talk
●Read
●Edit
●View history
Tools
Actions
●Read
●Edit
●View history
General
●What links here
●Related changes
●Upload file
●Special pages
●Permanent link
●Page information
●Cite this page
●Get shortened URL
●Download QR code
●Wikidata item
Print/export
●Download as PDF
●Printable version
Appearance
From Wikipedia, the free encyclopedia
Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[2] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[3] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.[medical citation needed]
Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.[4]
References[edit]
^
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. (January 2016). "Belatacept and Long-Term Outcomes in Kidney Transplantation". The New England Journal of Medicine. 374 (4): 333–43. doi:10.1056/NEJMoa1506027. hdl:2445/178537. PMID 26816011. S2CID 35661528.
^ "FDA approves Nulojix for kidney transplant patients" (Press release). U.S. Food and Drug Administration. 2011-06-15. Archived from the original on 19 June 2011. Retrieved 2011-06-16.
External links[edit]
-
"Belatacept". Drug Information Portal. U.S. National Library of Medicine.
t
e
|
---|
Intracellular (initiation) |
|
---|
Intracellular (reception) |
|
---|
Extracellular |
|
---|
Unsorted |
|
---|
t
e
Retrieved from "https://en.wikipedia.org/w/index.php?title=Belatacept&oldid=1187917123"
Categories:
●Engineered proteins
●Drugs developed by Bristol Myers Squibb
●Antineoplastic and immunomodulating drug stubs
Hidden categories:
●Articles with short description
●Short description matches Wikidata
●Drugs with non-standard legal status
●Chemicals that do not have a ChemSpider ID assigned
●Infobox drug articles without a structure image
●Articles without EBI source
●Articles without InChI source
●Drug has EMA link
●Drugboxes which contain changes to verified fields
●All articles with unsourced statements
●Articles with unsourced statements from December 2020
●All stub articles
●This page was last edited on 2 December 2023, at 07:01 (UTC).
●Text is available under the Creative Commons Attribution-ShareAlike License 4.0;
additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
●Privacy policy
●About Wikipedia
●Disclaimers
●Contact Wikipedia
●Code of Conduct
●Developers
●Statistics
●Cookie statement
●Mobile view